Axicabtagene ciloleucel (axi-cel), a CD19-targeted chimeric antigen receptor (CAR)-T cell therapy, has revolutionized the treatment of the disease, demonstrating superior levels of durable response in relapsed/refractory (R/R) DLBCL (9–11). Here, CD19 is linked to diffuse large B-cell lymphoma.